nicardipine has been researched along with Myocardial Infarction in 24 studies
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.
2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The acute and chronic haemodynamic effects of nicardipine were studied, at rest and during exercise, in 10 post-myocardial infarction patients with latent cardiac failure and no signs of residual myocardial ischaemia." | 9.06 | Acute and chronic effects of nicardipine on rest and exercise haemodynamics in post-myocardial infarction patients with latent cardiac failure. ( La Rovere, MT; Mortara, A; Opasich, C; Specchia, G, 1989) |
| "Acute effects of intravenous nicardipine (10 micrograms/kg) on systemic hemodynamics and cardiac function were evaluated in 17 patients with a healed myocardial infarction and no evidence of congestive heart failure." | 7.68 | Acute effects of intravenous nicardipine on hemodynamics and cardiac function in patients with a healed myocardial infarction and no evidence of congestive heart failure. ( Ishii, M; Ogawa, T; Sekiguchi, T; Sugishita, Y; Ushiyama, K; Yasui, K, 1991) |
| "The haemodynamic dose-response effects of the slow-calcium channel blocker nicardipine were evaluated in fifteen male patients with uncomplicated acute myocardial infarction." | 7.67 | Haemodynamic effects of nicardipine in acute myocardial infarction. ( Frais, MA; Hafizullah, M; Jackson, NC; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1984) |
| "To examine whether nicardipine, a dihydropyridine derivative, limits size of myocardial infarction, and to compare the protective effects of nicardipine administered before and early and late after coronary artery occlusion, 99mTc-labeled albumin microspheres were injected into the left atrium during 5 min temporary coronary artery occlusion to determine the extent of the hypoperfused zone (the area at risk)." | 7.67 | Comparative effects of nicardipine, a new calcium antagonist, on size of myocardial infarction after coronary artery occlusion in dogs. ( Endo, T; Fujita, S; Hayakawa, H; Iida, N; Kikuchi, K; Kiuchi, K; Nejima, J; Okumura, H, 1986) |
| " Nicardipine given by three different dosing schedules to baboons markedly limited myocardial infarction over a 6 h period of LAD occlusion." | 5.27 | Nicardipine in models of myocardial infarction. ( Alps, BJ; Calder, C; Wilson, A, 1985) |
| "The acute and chronic haemodynamic effects of nicardipine were studied, at rest and during exercise, in 10 post-myocardial infarction patients with latent cardiac failure and no signs of residual myocardial ischaemia." | 5.06 | Acute and chronic effects of nicardipine on rest and exercise haemodynamics in post-myocardial infarction patients with latent cardiac failure. ( La Rovere, MT; Mortara, A; Opasich, C; Specchia, G, 1989) |
| "Acute effects of intravenous nicardipine (10 micrograms/kg) on systemic hemodynamics and cardiac function were evaluated in 17 patients with a healed myocardial infarction and no evidence of congestive heart failure." | 3.68 | Acute effects of intravenous nicardipine on hemodynamics and cardiac function in patients with a healed myocardial infarction and no evidence of congestive heart failure. ( Ishii, M; Ogawa, T; Sekiguchi, T; Sugishita, Y; Ushiyama, K; Yasui, K, 1991) |
| "The haemodynamic dose-response effects of the slow-calcium channel blocker nicardipine were evaluated in fifteen male patients with uncomplicated acute myocardial infarction." | 3.67 | Haemodynamic effects of nicardipine in acute myocardial infarction. ( Frais, MA; Hafizullah, M; Jackson, NC; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1984) |
| "To examine whether nicardipine, a dihydropyridine derivative, limits size of myocardial infarction, and to compare the protective effects of nicardipine administered before and early and late after coronary artery occlusion, 99mTc-labeled albumin microspheres were injected into the left atrium during 5 min temporary coronary artery occlusion to determine the extent of the hypoperfused zone (the area at risk)." | 3.67 | Comparative effects of nicardipine, a new calcium antagonist, on size of myocardial infarction after coronary artery occlusion in dogs. ( Endo, T; Fujita, S; Hayakawa, H; Iida, N; Kikuchi, K; Kiuchi, K; Nejima, J; Okumura, H, 1986) |
| "Angiographic progression of coronary atherosclerosis is frequently observed in clinical practice and is used as an end point in clinical trials; however, its prognostic significance is unclear." | 2.67 | Prognostic significance of progression of coronary atherosclerosis. ( Craven, TE; Lespérance, J; Waters, D, 1993) |
| "Nicardipine hydrochloride is a newer agent that has undergone extensive evaluation in recent years." | 2.38 | Clinical pharmacology, pharmacokinetics, and hemodynamic effects of nicardipine. ( Josephson, MA; Singh, BN, 1990) |
| "Nicardipine has high affinity for the dihydropyridine-binding site and has been shown to inhibit the influx of extracellular calcium through membrane slow channels." | 2.37 | Animal pharmacology of nicardipine and its clinical relevance. ( Whiting, RL, 1987) |
| "Treatment with nicardipine, nitroprusside, and verapamil are equally effective in improving flow." | 1.36 | No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. ( Abdalrahman, IB; Dharmashankar, KC; Kloner, RA; Rezkalla, SH, 2010) |
| "Nicardipine therapy was well tolerated without adverse hemodynamic or chronotropic effects." | 1.33 | Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. ( Awar, M; Fischman, DL; Frankil, C; Huang, RI; Ogilby, JD; Patel, P; Savage, MP; Walinsky, P, 2006) |
| "Nicardipine-treated and control groups had similar jeopardy area values (41." | 1.28 | Effects of nicardipine, a calcium antagonist, on myocardial salvage and high energy phosphate stores in reperfused myocardial injury. ( Derugin, N; Higgins, CB; Holt, WW; Saeed, M; Wendland, MF; Wolfe, C, 1990) |
| "Nicardipine treatment significantly modified the general haemodynamic responses to LAD ligation particularly in maintaining a low LV systolic pressure and inhibiting elevation of LV end diastolic pressure." | 1.27 | The beneficial effect of nicardipine on the healing of myocardial infarcts in dogs. ( Alps, BJ; Calder, C; Scott-Park, FM; Wilson, A, 1983) |
| " Nicardipine given by three different dosing schedules to baboons markedly limited myocardial infarction over a 6 h period of LAD occlusion." | 1.27 | Nicardipine in models of myocardial infarction. ( Alps, BJ; Calder, C; Wilson, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (45.83) | 18.7374 |
| 1990's | 9 (37.50) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 2 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rezkalla, SH | 1 |
| Dharmashankar, KC | 1 |
| Abdalrahman, IB | 1 |
| Kloner, RA | 1 |
| Habibzadeh, MR | 1 |
| Thai, H | 1 |
| Movahed, MR | 1 |
| Huang, RI | 1 |
| Patel, P | 1 |
| Walinsky, P | 1 |
| Fischman, DL | 1 |
| Ogilby, JD | 1 |
| Awar, M | 1 |
| Frankil, C | 1 |
| Savage, MP | 1 |
| Fischell, TA | 1 |
| Subraya, RG | 1 |
| Ashraf, K | 1 |
| Perry, B | 1 |
| Haller, S | 1 |
| Seu, V | 1 |
| Abrile, PG | 1 |
| Boero, E | 1 |
| Magaia, O | 1 |
| Mocini, A | 1 |
| Castrignano, A | 1 |
| Maffei, P | 1 |
| Perugini, P | 1 |
| Livi, A | 1 |
| Silke, B | 1 |
| Verma, SP | 1 |
| Hafizullah, M | 1 |
| Reynolds, G | 1 |
| Frais, MA | 1 |
| Jackson, NC | 1 |
| Taylor, SH | 1 |
| Bando, S | 1 |
| Kakutani, A | 1 |
| Shinomiya, H | 1 |
| Noda, T | 1 |
| Minezono, K | 1 |
| Mori, H | 1 |
| Alps, BJ | 3 |
| Calder, C | 3 |
| Wilson, A | 3 |
| Scott-Park, FM | 1 |
| Connelly, CM | 1 |
| Waksmonski, C | 1 |
| Gagnon, MM | 1 |
| Lipsitz, LA | 1 |
| Waters, D | 1 |
| Craven, TE | 1 |
| Lespérance, J | 1 |
| Gillman, MW | 1 |
| Ross-Degnan, D | 1 |
| McLaughlin, TJ | 1 |
| Gao, X | 1 |
| Spiegelman, D | 1 |
| Hertzmark, E | 1 |
| Goldman, L | 1 |
| Soumerai, SB | 1 |
| Sullivan, AT | 1 |
| Baker, DJ | 1 |
| Drew, GM | 1 |
| Sandhu, R | 1 |
| Biro, GP | 1 |
| Ogawa, T | 1 |
| Sekiguchi, T | 1 |
| Ishii, M | 1 |
| Ushiyama, K | 1 |
| Yasui, K | 1 |
| Sugishita, Y | 1 |
| Singh, BN | 1 |
| Josephson, MA | 1 |
| Yusuf, S | 1 |
| Held, P | 1 |
| Furberg, C | 1 |
| Holt, WW | 1 |
| Wendland, MF | 1 |
| Derugin, N | 1 |
| Wolfe, C | 1 |
| Saeed, M | 1 |
| Higgins, CB | 1 |
| Whiting, RL | 1 |
| La Rovere, MT | 2 |
| Mortara, A | 1 |
| Opasich, C | 2 |
| Specchia, G | 2 |
| Cobelli, F | 1 |
| Riccardi, G | 1 |
| Calsamiglia, G | 1 |
| Nomura, H | 1 |
| Ogawa, S | 1 |
| Yasuma, F | 1 |
| Narita, G | 1 |
| Miyaguchi, K | 1 |
| Hama, Y | 1 |
| Sotobata, I | 1 |
| Endo, T | 1 |
| Nejima, J | 1 |
| Fujita, S | 1 |
| Kiuchi, K | 1 |
| Iida, N | 1 |
| Kikuchi, K | 1 |
| Hayakawa, H | 1 |
| Okumura, H | 1 |
3 reviews available for nicardipine and Myocardial Infarction
| Article | Year |
|---|---|
Prophylactic intragraft injection of nicardipine prior to saphenous vein graft percutaneous intervention for the prevention of no-reflow: a review and comparison to protection devices.
Topics: Angioplasty, Balloon, Coronary; Catheterization; Coronary Artery Bypass; Embolic Protection Devices; | 2011 |
Clinical pharmacology, pharmacokinetics, and hemodynamic effects of nicardipine.
Topics: Adrenergic beta-Antagonists; Animals; Cardiac Output, Low; Chemical Phenomena; Chemistry; Electrophy | 1990 |
Animal pharmacology of nicardipine and its clinical relevance.
Topics: Action Potentials; Animals; Calcium; Coronary Disease; Dose-Response Relationship, Drug; Drug Evalua | 1987 |
6 trials available for nicardipine and Myocardial Infarction
| Article | Year |
|---|---|
"Pharmacologic" distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention.
Topics: Aged; Cardiac Catheterization; Coronary Angiography; Coronary Artery Bypass; Coronary Vessels; Cost- | 2007 |
[Preliminary note on the use of calcium antagonists in ischemic cardiopathy].
Topics: Adult; Angina Pectoris; Benzazepines; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; | 1984 |
Effects of isosorbide dinitrate and nicardipine hydrochloride on postprandial blood pressure in elderly patients with stable angina pectoris or healed myocardial infarction.
Topics: Aged; Angina Pectoris; Blood Pressure; Cross-Over Studies; Double-Blind Method; Eating; Female; Huma | 1995 |
Prognostic significance of progression of coronary atherosclerosis.
Topics: Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; | 1993 |
Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies.
Topics: Angina, Unstable; Calcium Channel Blockers; Denmark; Humans; Myocardial Infarction; Nicardipine; Nif | 1991 |
Acute and chronic effects of nicardipine on rest and exercise haemodynamics in post-myocardial infarction patients with latent cardiac failure.
Topics: Clinical Trials as Topic; Exercise Test; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myo | 1989 |
15 other studies available for nicardipine and Myocardial Infarction
| Article | Year |
|---|---|
No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy.
Topics: Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Cardiac Catheterization; Female; Fractiona | 2010 |
Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Coronary A | 2006 |
Haemodynamic effects of nicardipine in acute myocardial infarction.
Topics: Blood Pressure; Calcium Channel Blockers; Cardiac Output; Dose-Response Relationship, Drug; Heart Ra | 1984 |
[Effects of nicardipine hydrochloride on hemodynamics and regional myocardial functions in experimental coronary ischemia].
Topics: Animals; Calcium Channel Blockers; Dogs; Hemodynamics; Myocardial Contraction; Myocardial Infarction | 1983 |
The beneficial effect of nicardipine compared with nifedipine and verapamil in limiting myocardial infarct size in baboons.
Topics: Animals; Calcium Channel Blockers; Female; Hemodynamics; Lidocaine; Male; Myocardial Infarction; Nic | 1983 |
The beneficial effect of nicardipine on the healing of myocardial infarcts in dogs.
Topics: Animals; Blood Pressure; Dogs; Hemodynamics; Male; Myocardial Infarction; Myocardium; Nicardipine; N | 1983 |
Effects of long-acting versus short-acting calcium channel blockers among older survivors of acute myocardial infarction.
Topics: Aged; Calcium Channel Blockers; Dihydropyridines; Diltiazem; Female; Humans; Male; Myocardial Infarc | 1999 |
Effect of calcium channel blocking agents on infarct size after ischaemia-reperfusion in anaesthetised pigs: relationship between cardioprotection and cardiodepression.
Topics: Animals; Aspirin; Coronary Vessels; Depression, Chemical; Heart; Hemodynamics; Injections, Intra-Art | 1991 |
Changes in the myocardial area at risk, infarct size, and collateral flow following nicardipine infusion in dogs.
Topics: Animals; Arterial Occlusive Diseases; Blood Flow Velocity; Collateral Circulation; Coronary Circulat | 1991 |
Acute effects of intravenous nicardipine on hemodynamics and cardiac function in patients with a healed myocardial infarction and no evidence of congestive heart failure.
Topics: Adult; Aged; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Middle Aged; Myocardial In | 1991 |
Effects of nicardipine, a calcium antagonist, on myocardial salvage and high energy phosphate stores in reperfused myocardial injury.
Topics: Adenosine Triphosphate; Animals; Cats; Magnetic Resonance Spectroscopy; Myocardial Infarction; Myoca | 1990 |
Does the study of anaerobic metabolism give quantitative information on left ventricular dysfunction during exercise?
Topics: Adult; Anaerobiosis; Exercise Test; Exercise Therapy; Hemodynamics; Humans; Lactates; Male; Middle A | 1988 |
[The effects of nicardipine on hemodynamics, regional myocardial function and myocardial metabolism in the dog with coronary artery occlusion].
Topics: Animals; Dogs; Energy Metabolism; Hemodynamics; Myocardial Infarction; Myocardium; Nicardipine | 1987 |
Comparative effects of nicardipine, a new calcium antagonist, on size of myocardial infarction after coronary artery occlusion in dogs.
Topics: Animals; Arrhythmias, Cardiac; Coronary Circulation; Coronary Disease; Dogs; Female; Hemodynamics; M | 1986 |
Nicardipine in models of myocardial infarction.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Dogs; Electrocardiography; Heart Conducti | 1985 |